Reunion Neuroscience (TSX:REUN) Growth Rank : 0 (As of Apr. 28, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Reunion Neuroscience Growth Rank?

Reunion Neuroscience has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Reunion Neuroscience Growth Rank Related Terms

Thank you for viewing the detailed overview of Reunion Neuroscience's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Reunion Neuroscience (TSX:REUN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reunion Neuroscience Inc (TSX:REUN) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Duncan Street, Lower North Suite, Toronto, ON, CAN, M5V 2C3

Website

https://www.reunionneuro.com

Reunion Neuroscience Inc is engaged in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company's asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment-resistant depression as a potential fast-acting antidepressant with durable efficacy.